In PD, the genetic stratification of LRRK2, GBA, and SNCA mutations has reshaped the practice of DBS, as these genetic data are utilized for personalized electrode/treatment positioning based on genetic modifiable variables, ultimately leading to improvements in motor and non-motor variables. The gene discussed is GBA1; the disease is Parkinson disease.